Takeda Pharmaceutical Company Limited
4502.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥6,967,567 | ¥6,506,548 | ¥6,750,369 | ¥5,469,126 |
| - Cash | ¥233,742 | ¥205,190 | ¥229,557 | ¥849,695 |
| + Debt | ¥5,088,590 | ¥5,463,391 | ¥4,861,692 | ¥4,810,649 |
| Enterprise Value | ¥11,822,415 | ¥11,764,749 | ¥11,382,504 | ¥9,430,080 |
| Revenue | ¥4,581,551 | ¥4,263,762 | ¥4,027,478 | ¥3,569,006 |
| % Growth | 7.5% | 5.9% | 12.8% | – |
| Gross Profit | ¥2,455,188 | ¥2,324,911 | ¥2,298,316 | ¥2,043,633 |
| % Margin | 53.6% | 54.5% | 57.1% | 57.3% |
| EBITDA | ¥1,127,443 | ¥927,954 | ¥1,184,514 | ¥1,042,820 |
| % Margin | 24.6% | 21.8% | 29.4% | 29.2% |
| Net Income | ¥107,928 | ¥144,067 | ¥317,017 | ¥230,059 |
| % Margin | 2.4% | 3.4% | 7.9% | 6.4% |
| EPS Diluted | 67.23 | 91.16 | 201.94 | 145.87 |
| % Growth | -26.3% | -54.9% | 38.4% | – |
| Operating Cash Flow | ¥962,493 | ¥640,321 | ¥877,217 | ¥1,021,218 |
| Capital Expenditures | -¥200,795 | -¥175,420 | -¥140,657 | -¥123,252 |
| Free Cash Flow | ¥761,698 | ¥464,901 | ¥736,560 | ¥897,966 |